Valeant Pharmaceuticals Intl Inc (VRX) Put Volume Pops After Fraud Accusations

Valeant Pharmaceuticals Intl Inc (VRX) puts are hot after a chilling Citron Research report

by Andrea Kramer

Published on Oct 21, 2015 at 11:38 AM

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are plummeting -- and were temporarily halted -- on a devastating short-seller report. The stock was last seen roughly 24% lower at $111.50, and earlier touched a two-year low of $98.35. Against this backdrop, the stock has landed on the short-sale restricted list, and option bears are blitzing the biotech.

At last check, roughly 65,000 VRX puts have changed hands -- 10 times the average intraday put volume, and nearly twice the number of VRX calls exchanged. The equity's 30-day at-the-money implied volatility has spiked to a fresh 52-week high of 144.70%, more than doubling from yesterday's close.

Most popular thus far is the weekly 10/23 95-strike put, which has garnered a healthy amount of what looks like buy-to-open action. By purchasing the puts at a volume-weighted average price (VWAP) of $3.94, the buyers will make money if VRX sinks beneath $91.06 -- territory not explored since mid-2013 -- by Friday's close, when the options expire. Delta on the put sat at zero yesterday -- when the contract was even deeper out of the money -- but has surged to negative 0.23 today, implying a 23% chance of expiring in the money.

Even before today, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was under fire for its drug pricing. As alluded to earlier, the equity's foray into double-digit territory today was prompted by a report from Citron Research -- "Valeant: Could this be the Pharmaceutical Enron?" -- which accused the company of fraud and a "cover up." 

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Google Postpones Android Reveal, "Now is Not the Time to Celebrate"
"Now is not the time to celebrate," Google said in a message on its website
ZNGA Zooms to 8-Year High on Billion-Dollar Deal
ZNGA is planning to buy Peak for $1.8 billion
Huge New Legal Marijuana Market Has Shortage Crisis
250 million Europeans have access to medical marijuana. There's already a shortage....